Vera Therapeutics Inc at Citi Global Healthcare Conference Transcript
The CEO, Marshall Fordyce welcome. Thank you. And special guests, Robert Brenner, CMO. Thank you very much as well for joining us up here. So a lot to talk about.
You're late stage, of course, again.
But maybe just set the stage and tell us where you are, tell us about the recent data, of course, at ASN. -- and what the time lines are for getting the market.
Great. Yigal, great to see you, and thanks for your great science-based coverage in the space. We need it today. I'm Marshall Fordyce. I'm the Founder and CEO of Vera.
I am a physician by background. We're incredibly excited to bring Vera to the stage. We have now read out Phase III data that are both positive and very compelling in a new category creating area of kidney medicine in glomerulonephritis, specifically IgA nephropathy. We had Phase III data that was shared at the opening plenary session of the ASN or American Society of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
